Lack of PMN310 binding to perivascular amyloid plaque in Alzheimer’s brain tissue may eliminate dose-limiting brain swelling seen with aducanumab
TORONTO and CAMBRIDGE, MA, Jan. 4, 2018 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and…
